13 research outputs found
Patientâreported outcomes after 3âdimensional conformal, intensityâmodulated, or proton beam radiotherapy for localized prostate cancer
BACKGROUND: Recent studies have suggested differing toxicity patterns for patients with prostate cancer who receive treatment with 3âdimensional conformal radiotherapy (3DCRT), intensityâmodulated radiotherapy (IMRT), or proton beam therapy (PBT). METHODS: The authors reviewed patientâreported outcomes data collected prospectively using validated instruments that assessed bowel and urinary quality of life (QOL) for patients with localized prostate cancer who received 3DCRT (n = 123), IMRT (n = 153) or PBT (n = 95). Clinically meaningful differences in mean QOL scores were defined as those exceeding half the standard deviation of the baseline mean value. Changes from baseline were compared within groups at the first postâtreatment followâup (2â3 months from the start of treatment) and at 12 months and 24 months. RESULTS: At the first postâtreatment followâup, patients who received 3DCRT and IMRT, but not those who received PBT, reported a clinically meaningful decrement in bowel QOL. At 12 months and 24 months, all 3 cohorts reported clinically meaningful decrements in bowel QOL. Patients who received IMRT reported clinically meaningful decrements in the domains of urinary irritation/obstruction and incontinence at the first postâtreatment followâup. At 12 months, patients who received PBT, but not those who received IMRT or 3DCRT, reported a clinically meaningful decrement in the urinary irritation/obstruction domain. At 24 months, none of the 3 cohorts reported clinically meaningful changes in urinary QOL. CONCLUSIONS: Patients who received 3DCRT, IMRT, or PBT reported distinct patterns of treatmentârelated QOL. Although the timing of toxicity varied between the cohorts, patients reported similar modest QOL decrements in the bowel domain and minimal QOL decrements in the urinary domains at 24 months. Prospective randomized trials are needed to further examine these differences. Cancer 2013. © 2013 American Cancer Society. Prostate cancer patients who receive 3âdimensional conformal radiotherapy, intensityâmodulated radiotherapy, or proton beam therapy report distinct patterns of treatmentârelated quality of life. Although the timing of toxicity varies between cohorts, patients report similar modest qualityâofâlife decrements in the bowel domain and minimal QOL decrements in the urinary domains at 24 months.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/97476/1/27956_ftp.pd